RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
Laurent Peyrin-Biroulet 1
J. Casey Chapman 2, 3, 4
Jean-Frédéric Colombel 5
Flavio Caprioli 6
Geert R. D'Haens 7
Marc Ferrante 8
Stefan Schreiber 9
Raja Atreya 10
Silvio Danese 11
James O. Lindsay 12
Peter Bossuyt 13
Britta Siegmund 14
Peter Irving 15
Remo Panaccione 16
Ezequiel Neimark 17
Kori Wallace 17
Toni Anschutz 17
Kristina Kligys 17
Rachel Duan 18
Valerie Pivorunas 18
Xiu Huang 18
Sofie Berg 18
Lei Shu 18
Marla C. Dubinsky 19
1 Inserm U1256, Nancy University Hospital, Vandoeuvre-les-Nancy, France
2 Crohn's and Colitis Center at the Baton Rouge General, Baton Rouge, United States
3 GI Alliance, Baton Rouge, United States
4 Louisiana State University Health Sciences Center, Baton Rouge, United States
5 Icahn School of Medicine at Mount Sinai, USA, United States
6 University of Milan, Milano, Italy
7 AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
8 University Hospitals Leuven, Leuven, Belgium
9 University Hospital Schleswig-Holstein, Kiel, Germany
10 University Erlangen-Nuremberg, Erlangen, Germany
11 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Netherlands
12 Digestive Disorders Clinical Academic Unit, Barts & The London School of Medicine, London, United Kingdom
13 Imelda General Hospital, Bonheiden, Belgium
14 Charité - Universitätsmedizin Berlin, Berlin, Germany
15 Guy´s and St Thomas´ Hospital, London, United Kingdom
16 University of Calgary, Calgary, Canada
17 AbbVie, North Chicago, United States
18 Abbvie, North Chicago, United States
19 Mount Sinai Hospital, Mount Sinai, New York City, United States
Topic
IBD
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]